The estimated Net Worth of Jonathan G Drachman is at least $6.08 Milion dollars as of 10 November 2021. Jonathan Drachman owns over 200,000 units of Neoleukin Therapeutics stock worth over $698,000 and over the last 11 years he sold NLTX stock worth over $1,561,980. In addition, he makes $3,823,040 as President, Chief Executive Officer a Director at Neoleukin Therapeutics.
Sign up
Jonathan Drachman NLTX stock SEC Form 4 insiders trading
Jonathan has made over 26 trades of the Neoleukin Therapeutics stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 200,000 units of NLTX stock worth $172,000 on 10 November 2021.
The largest trade he's ever made was buying 250,000 units of Neoleukin Therapeutics stock on 9 September 2019 worth over $782,500. On average, Jonathan trades about 18,295 units every 56 days since 2013. As of 10 November 2021 he still owns at least 200,000 units of Neoleukin Therapeutics stock.
You can see the complete history of Jonathan Drachman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jonathan Drachman biography
Dr. Jonathan G. Drachman M.D. serves as President, Chief Executive Officer, Director of the Company. He has served as a director and the Chief Executive Officer of Neoleukin since November 2018. From November 2004 to May 2018, Dr. Drachman held several positions at Seattle Genetics, Inc., culminating in the position of Chief Medical Officer and Executive Vice President of Research and Development. From 1998 to 2004, he was a faculty member in the Division of Hematology at the University of Washington, and a Senior Investigator in the Division of Research and Education at Puget Sound Blood Center. He currently serves on the board of directors of Harpoon Therapeutics, Inc. and Calithera Biosciences, Inc. Dr. Drachman received his M.D. at Harvard Medical School and his A.B. in Biochemistry from Harvard College. He completed his residency in internal medicine and a fellowship in medical oncology at the University of Washington. The Nominating and Governance Committee believes that Dr. Drachman is qualified to serve on our Board of Directors because he has extensive experience in the biopharmaceutical industry and service as our Chief Executive Officer.
What is the salary of Jonathan Drachman?
As the President, Chief Executive Officer a Director of Neoleukin Therapeutics, the total compensation of Jonathan Drachman at Neoleukin Therapeutics is $3,823,040. There are no executives at Neoleukin Therapeutics getting paid more.
How old is Jonathan Drachman?
Jonathan Drachman is 58, he's been the President, Chief Executive Officer a Director of Neoleukin Therapeutics since 2019. There are 3 older and 8 younger executives at Neoleukin Therapeutics. The oldest executive at Neoleukin Therapeutics, Inc. is Lewis Williams, 70, who is the Independent Director.
What's Jonathan Drachman's mailing address?
Jonathan's mailing address filed with the SEC is C/O HARPOON THERAPEUTICS, INC., 611 GATEWAY BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Neoleukin Therapeutics
Over the last 5 years, insiders at Neoleukin Therapeutics have traded over $425,653 worth of Neoleukin Therapeutics stock and bought 6,490,231 units worth $38,477,971 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Group, Llc Green Jeremy Red... a Bros. Advisors Lp667, L.P.B.... On average, Neoleukin Therapeutics executives and independent directors trade stock every 37 days with the average trade being worth of $593,084. The most recent stock trade was executed by Bros. Advisors Lp667, L.P.B... on 15 August 2023, trading 2,285,342 units of NLTX stock currently worth $1,462,619.
What does Neoleukin Therapeutics do?
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
What does Neoleukin Therapeutics's logo look like?
Complete history of Jonathan Drachman stock trades at Calithera Biosciences Inc, Seagen Inc, Harpoon Therapeutics a Neoleukin Therapeutics
Neoleukin Therapeutics executives and stock owners
Neoleukin Therapeutics executives and other stock owners filed with the SEC include:
-
Jonathan Drachman,
President, Chief Executive Officer, Director -
Dr. Jonathan G. Drachman,
CEO, Pres & Director -
Robert Ho,
Chief Financial Officer -
Todd Simpson,
Independent Chairman of the Board -
Lewis Williams,
Independent Director -
Sarah Noonberg,
Independent Director -
M. Cantey Boyd,
Independent Director -
Erin Lavelle,
Director -
Martin Babler,
Director -
Samantha Willing,
Vice President - People -
Leslie Aberman,
Vice President - Legal Affairs and Intellectual Property -
Robert Ho,
Chief Financial Officer, Secretary -
Dr. Bill Arthur,
VP & Head of Research -
Dr. Priti Patel M.D., M.S.,
Chief Medical Officer -
Umut Ulge,
VP of Clinical Devel. -
Dr. Carl Walkey Ph.D.,
Sr. VP of Corp. Devel. -
Holly K. Vance,
Gen. Counsel -
Dr. David Baker,
Co-founder & Member of Scientific Advisory Board -
Kamran Alam,
Sr. Strategic Advisor -
Group, Llc Green Jeremy Red...,
-
Sean Michael Smith,
Interim CFO, Prin Acct Off -
Holly Vance,
General Counsel -
Sean P. Nolan,
Director -
Bros. Advisors Lp Baker Bro...,
-
Priti Patel,
-
Carl Walkey,
Senior Vice President -
Bros. Advisors Lp667, L.P.B...,
-
Erin M. Lavelle,
Director -
Bros. Advisors Lp667, L.P.B...,
-
Donna Cochener,
General Counsel, SVP Legal -
Rohan Palekar,
Director